Amyvid florbetapir regulatory update

The European Commission approved Amyvid florbetapir from Eli Lilly as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Lilly said it will begin discussions with reimbursement authorities in the "near future" and will launch the product in select territories next quarter. ...